title: Simultaneous use of mifepristone and misoprostol for early pregnancy termination.
abstract: OBJECTIVE
  Simultaneous mifepristone 200mg and vaginal misoprostol 800μg produces a complete abortion rate of approximately 90% at up to 63 days of gestation. The aim of this study was to determine the effectiveness of concurrent administration of mifepristone 200mg and vaginal misoprostol 600μg with respect to early medical abortion.
  
  
  METHODS
  A total of 254 women with undesired pregnancies of less than 49 days of gestation were enrolled. All women received oral mifepristone 200mg and vaginal misoprostol 600μg concurrently. Follow-up assessment by transvaginal ultrasonography was performed 3 days and 2 weeks after treatment.
  
  
  RESULTS
  Efficacy outcome was analyzed for 242 women (95.3%) after excluding 12 individuals lost to follow-up. The complete abortion rate was 92.6%. The mean induction to abortion interval was about 5.8hours. The mean bleeding duration was about 12.6 days. The women indicated that the side effects were tolerable and 90% of them said that their experience was satisfactory.
  
  
  CONCLUSIONS
  Concurrent administration of oral mifepristone 200mg and vaginal misoprostol 600μg is an efficacious regimen for medical abortion of pregnancies up to 49 days of gestation.
authors.affiliation: Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan.
authors.forename: Yiu-Tai
authors.initials: YT
authors.lastname: Li
authors.forename: James Ching-Hung
authors.initials: JC
authors.lastname: Hsieh
authors.forename: Guang-Qiong
authors.initials: GQ
authors.lastname: Hou
authors.forename: Tien-Hui
authors.initials: TH
authors.lastname: Chen
authors.forename: Yi-Chih
authors.initials: YC
authors.lastname: Chu
authors.forename: Ta-Chin
authors.initials: TC
authors.lastname: Lin
authors.forename: Long-Ching
authors.initials: LC
authors.lastname: Kuan
authors.forename: Mau
authors.initials: M
authors.lastname: Lin
authors.forename: Hsun-Han
authors.initials: HH
authors.lastname: Tang
authors.forename: Tsung-Cheng
authors.initials: TC
authors.lastname: Kuo
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone